BPC-157 Overdose or Accidental Extra Dose: What to Do
Evidence note: Regulatory records, toxicology research, and poison-center guidance were rechecked on August 29, 2026. Medical review of this revision is pending; the historical review date remains visible above.
At a glance
- FDA approval / BPC-157 is not an FDA-approved drug
- Validated human overdose threshold / not established
- Published human overdose cases or protocol / none identified in the sources reviewed
- Specific antidote / none established
- Best immediate resource in the U.S. / Poison Control, 1-800-222-1222 or poison.org
- Emergency threshold / collapse, seizure, trouble breathing, or inability to awaken: call 911
- Human safety evidence / a handful of small, short studies that were not designed to establish an overdose threshold
- Animal toxicology / useful for hazard research, not a personal clearance calculation
- Product uncertainty / concentration, impurities, aggregation, storage, and route can change risk
The First Decision Is Triage, Not Dose Conversion
If an exposure may have happened, do not spend the first hour searching for a supposedly “safe” BPC-157 ceiling. None has been validated in humans. Poison Control bases its recommendation on the exact substance, amount, age, weight when needed, route, symptoms, and time since exposure—not on one universal cutoff 1.
| Situation now | Action | Why |
|---|---|---|
| The person collapses, has a seizure, has trouble breathing, or cannot be awakened | Call 911 immediately | These are Poison Control's emergency criteria and should not wait for peptide-specific interpretation 2 |
| The person is awake and stable, but injected, swallowed, inhaled, or otherwise used more than intended—or the amount is uncertain | In the U.S., call Poison Control at 1-800-222-1222 or use poison.org now | Poison specialists can triage injected and other exposures case by case; Poison Control says not to wait for symptoms 1 |
| Symptoms are present but do not meet the emergency criteria above | Contact Poison Control now and follow its case-specific direction; seek emergency care if instructed or if symptoms worsen | BPC-157 lacks a validated home-observation window or symptom-based self-clearance rule |
| The product name, concentration, or contents are unclear | Treat the identity uncertainty as part of the exposure and call Poison Control | A label claim does not establish what was administered, especially for an unapproved or compounded product |
This is intentionally not a home-treatment algorithm. It does not prescribe vital-sign intervals, laboratory panels, fluids, anti-nausea medication, or an observation duration. Those choices depend on the person, product, route, co-exposures, symptoms, and clinical assessment.
Build the Exposure Record Before Details Disappear
The most useful artifact is not a dose calculator. It is a compact record that lets a poison specialist identify the actual uncertainty.
| Capture | Record exactly | Do not substitute |
|---|---|---|
| Product | Full label name, manufacturer or pharmacy, lot number, ingredients, and a photo of every panel | “BPC” or a seller's webpage |
| Strength and container | Units exactly as printed, such as mg, mcg, or mg/mL, plus the original container size | A converted number you are not confident about |
| Amount | Intended amount, possible amount used, and how that estimate was made | A best-case guess |
| Route and form | Injection, oral liquid, capsule, nasal product, cream, or another route; note any diluent | Assuming evidence from one route applies to another |
| Timing | Time of exposure and when any symptoms began | “A while ago” |
| Person and context | Age, weight if known, medical conditions, allergies, current medicines, alcohol, supplements, and other substances used | Leaving out a co-exposure because it seems unrelated |
| Current condition | Symptoms, whether they are changing, and any objective measurements already taken | Repeated self-checks that delay the call |
Keep the container and packaging available. Do not take another peptide or medication to “balance” the exposure. For something swallowed, Poison Control advises against inducing vomiting 2.
Why the Number on the Vial Cannot Answer the Safety Question
“How many milligrams is an overdose?” sounds precise, but it collapses three separate unknowns:
- Human dose-response: no human study has established the exposure at which toxicity begins.
- Product identity: the labeled peptide, its concentration, impurities, aggregates, sterility, and storage history may not be fully characterized.
- Route: oral, subcutaneous, intramuscular, intravenous, nasal, rectal, and transdermal exposure are not interchangeable.
FDA's 2026 review is unusually direct:
“There is insufficient clinical safety information to characterize the safety profile of BPC-157 (free base) and BPC-157 acetate.” — U.S. Food and Drug Administration, BPC-157 briefing document, p. 42 3
That is a statement about missing evidence, not proof that every exposure causes harm. It also is not an endorsement of any compounded product or a claim about an individual outcome.
FDA separately notes possible immunogenicity and difficulties characterizing peptide-related impurities and the active pharmaceutical ingredient in compounded BPC-157 4. A reaction could therefore involve the intended peptide, another ingredient, contamination, a product-quality problem, or some combination. The exposure record preserves those possibilities for the clinician or toxicologist.
What the Evidence Actually Covers
| Evidence layer | What it found | What it cannot establish for an accidental exposure |
|---|---|---|
| FDA review of human literature and reports | FDA found five small clinical studies using several routes and three FAERS reports through December 4, 2025. The studies were short, small, and had limited safety reporting; causality could not be assigned from the reports 3 | A toxic dose, expected symptom sequence, safe observation time, or antidote |
| Two-person IV pilot | Two adults who had previously received BPC-157 were given study infusions and reported no adverse effects during the study 5 | Safety for a different person, product, route, amount, repeated exposure, allergy, contamination, or overdose |
| 2025 systematic review | Of 36 included musculoskeletal studies, 35 were preclinical and one was a small retrospective clinical study; the review found no clinical safety data in that literature set 6 | A clinically tested excess-dose threshold or management protocol |
| Animal toxicity study | BPC-157 was studied in mice, rats, rabbits, and dogs, with no serious toxicity reported by the investigators under those experimental conditions 7 | Direct conversion of an animal no-observed-adverse-effect level into a safe human amount |
| Compounding status | Compounded drugs are not FDA-approved and do not undergo FDA premarket verification for safety, effectiveness, or quality 8 | Confirmation that a particular vial matches its label or published study material |
The conflict is not “animal studies say safe, FDA says dangerous.” The animal work studied defined material under controlled conditions. FDA's conclusion concerns the missing and incomplete evidence needed to characterize human use, routes, formulations, and product-quality risks. Those are different questions.
Three Claims to Reject
“No animal died, so this human exposure is below the lethal dose”
The animal paper did not establish a human lethal dose. FDA also noted that route-specific bioavailability gaps prevent using the intramuscular animal findings to estimate safety margins for the nominated oral, rectal, subcutaneous, and nasal routes 3. Body-size arithmetic cannot repair a missing human dose-response study.
“Two people tolerated a larger amount, so a smaller amount is safe”
A study of two previously exposed adults is a signal worth recording, but it has essentially no power to detect uncommon reactions or define a threshold across products and routes 5. “No event observed” is not the same result as “no event can occur.”
“No symptoms yet means the exposure is over”
There is no validated BPC-157 symptom-free observation period. Poison Control explicitly advises people with a suspected poisoning to get help immediately rather than wait for symptoms 1. A poison specialist can decide whether home observation, evaluation, or another action fits the actual exposure.
After the Immediate Question Is Resolved
Document what happened: the product, lot, seller or dispensing pharmacy, concentration, route, estimated amount, timeline, symptoms, advice received, and outcome. A clinician can decide whether the event or a suspected product-quality problem should be reported through FDA MedWatch. Do not restart the product solely because symptoms resolved; the exposure does not establish a safe future regimen.
For the wider evidence context, see the BPC-157 evidence overview, the separate analysis of BPC-157 drug-interaction uncertainty, and the framework for distinguishing approved, compounded, and experimental peptide products.
Frequently asked questions
What amount of BPC-157 is an overdose?
Should I call Poison Control if I feel fine?
Is there an antidote for BPC-157?
Do animal studies prove that a large accidental dose is safe?
Can I monitor at home for a few hours?
What if the vial came from a compounding pharmacy?
References
- National Capital Poison Center. Get Help Online or by Phone. Accessed August 29, 2026. Poison Control
- National Capital Poison Center. First Aid Guidelines. Accessed August 29, 2026. Poison Control
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Briefing Document: BPC-157-Related Bulk Drug Substances (BPC-157 Free Base and BPC-157 Acetate). July 23-24, 2026. FDA PDF
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Accessed August 29, 2026. FDA
- Lee E; Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative therapies in health and medicine. 2025 Sep;31(5):20-24. PMID 40131143. https://pubmed.ncbi.nlm.nih.gov/40131143/
- Vasireddi N; Hahamyan H; Salata MJ; Karns M; Calcei JG; Voos JE; Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery. 2025 Nov;21(4):485-495. DOI 10.1177/15563316251355551. PMID 40756949. PMCID PMC12313605. https://pubmed.ncbi.nlm.nih.gov/40756949/
- Xu C; Sun L; Ren F; Huang P; Tian Z; Cui J; Zhang W; Wang S; Zhang K; He L; Zhang W; Zhang C; Hao Q; Zhang Y; Li M; Li W. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory toxicology and pharmacology : RTP. 2020 Jul;114:104665. DOI 10.1016/j.yrtph.2020.104665. PMID 32334036. https://pubmed.ncbi.nlm.nih.gov/32334036/
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Accessed August 29, 2026. FDA